Platform trials, built around a master protocol that allows multiple treatment arms to be added or dropped over time within a single overarching trial infrastructure, have moved from an academic curiosity into mainstream use across oncology and, increasingly, infectious disease and other therapeutic areas.
The core economic advantage comes from shared infrastructure. A common control arm, shared statistical analysis framework, and standing site network mean that adding a new experimental arm to an existing platform trial requires substantially less upfront investment than launching a standalone trial from scratch, particularly for the site activation and control group enrollment that consume a large share of traditional trial timelines and budgets.
Statistical complexity increases in ways that require careful upfront planning. Managing multiple concurrent arms with different randomization ratios, handling arms that enter or exit the platform at different times, and controlling the overall false positive rate across a trial that may test many hypotheses over its lifetime all require statistical expertise that goes well beyond a standard two-arm trial design.
Governance structures for platform trials tend to be more elaborate than traditional trials, often involving an independent steering committee responsible for decisions about which new arms to add, when to drop an underperforming arm, and how to allocate the shared control group across multiple sponsors when a platform involves more than one company’s assets.
The model works best in disease areas with a stable, well-characterized patient population and a reasonably predictable pipeline of candidate treatments to test, conditions that made oncology and, more recently, pandemic-response infectious disease research natural early adopters, though the approach is beginning to extend into other chronic disease areas with similar characteristics.
Deep Dive coverage examining how specific platform trials have structured their governance and statistical frameworks, and what has and has not worked as arms have entered and exited over time, such as the analysis published by The Clinical Trial Vanguard, gives sponsors considering their own master protocol a more concrete reference than the general concept alone provides.
